{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T03:04:43Z","timestamp":1763348683799,"version":"3.37.3"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Urothelial tract cancer (UTC) ranks as the tenth most prevalent cancer and holds the seventh position in terms of mortality worldwide. Despite its prevalence and mortality ranking, there are still gaps in the knowledge of the mutational landscape in patients with advanced disease who have limited therapeutic options after multiple lines of prior treatment. This study compares the genomic and transcriptomic landscape, and targeted treatment options between metastatic UTC (mUTC) patients treated with multiple lines of therapy compared to newly diagnosed, untreated Muscle Invasive Bladder Cancer (MIBC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We compared genomic and clinical data from two cohorts: mUTC patients who received multiple lines of therapy and were referred to the Copenhagen Prospective Personalized Oncology (CoPPO) project at Rigshospitalet, University of Copenhagen. Data for MIBC UTC patients were acquired from the Cancer Genome Atlas Bladder Cancer (TCGA BLCA) cohort. Biopsies in CoPPO were performed at the time of enrollment. 523 highly important cancer-related genes (TrueSight Oncology-500 targeted sequencing panel) were used from both cohorts for comparative analysis. Analyses included RNA count data to compare predicted molecular subtypes in each cohort separately.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Patients from the CoPPO cohort had a lower median age at first-line treatment than the TCGA BLCA cohort, with no significant gender disparity. The predominant histology was urothelial cell carcinoma in both cohorts. Genomic analysis revealed no significant difference between the top mutated genes in the two cohorts, specifically looking into DNA damage repair genes. Molecular subtyping indicated a higher frequency of neuroendocrine differentiation in the CoPPO cohort. 13% of patients in the CoPPO cohort received targeted therapy based on genomic findings, and 16% received non-targeted treatment, totaling 29% receiving CoPPO treatment (9 patients). The remaining 71% received best supportive care. Kaplan-Meier analysis showed a non-significant survival benefit for the intervention group in the CoPPO cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>When focusing on 523 highly relevant cancer genes, the mutational profile of mUTC patients who have undergone numerous treatment lines resembles that of newly diagnosed MIBC. These alterations can be targeted, indicating the potential advantage of early genomic testing for personalized treatment within clinical trials.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-024-05850-y","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T13:02:00Z","timestamp":1720443720000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Similar genetic profile in early and late stage urothelial tract cancer"],"prefix":"10.1007","volume":"150","author":[{"given":"Dag Rune","family":"Stormoen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristoffer Staal","family":"Rohrberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kent William","family":"Mouw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrine","family":"\u00d8rum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoltan","family":"Szallasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik Otzen","family":"Bagger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helle","family":"Pappot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"key":"5850_CR1","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.7754\/CLIN.LAB.2017.170516","volume":"63","author":"LB Ahlborn","year":"2017","unstructured":"Ahlborn LB, Madsen M, Jonson L et al (2017) Concordance of mutation detection in circulating Tumor DNA in early clinical trials using different blood Collection Protocols. Clin Lab 63:1755\u20131759. https:\/\/doi.org\/10.7754\/CLIN.LAB.2017.170516","journal-title":"Clin Lab"},{"key":"5850_CR2","doi-asserted-by":"publisher","first-page":"32570","DOI":"10.18632\/oncotarget.25948","volume":"9","author":"LB Ahlborn","year":"2018","unstructured":"Ahlborn LB, Tuxen IV, Mouliere F et al (2018) Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors. Oncotarget 9:32570\u201332579. https:\/\/doi.org\/10.18632\/oncotarget.25948","journal-title":"Oncotarget"},{"key":"5850_CR3","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1200\/JCO.2011.38.6979","volume":"30","author":"J Bellmunt","year":"2012","unstructured":"Bellmunt J, Von Der Maase H, Mead GM et al (2012) Randomized phase III study comparing paclitaxel\/cisplatin\/ gemcitabine and gemcitabine\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC intergroup study 30987. J Clin Oncol 30:1107\u20131113. https:\/\/doi.org\/10.1200\/JCO.2011.38.6979","journal-title":"J Clin Oncol"},{"key":"5850_CR4","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/path.5318","volume":"249","author":"C Bernardo","year":"2019","unstructured":"Bernardo C, Eriksson P, Marzouka N, al dain et al (2019) Molecular pathology of the luminal class of urothelial tumors. J Pathol 249:308\u2013318. https:\/\/doi.org\/10.1002\/path.5318","journal-title":"J Pathol"},{"key":"5850_CR5","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1158\/2159-8290.CD-11-0206\/42935","volume":"2","author":"NJ Birkbak","year":"2012","unstructured":"Birkbak NJ, Wang ZC, Kim JY et al (2012) Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2:366\u2013375. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0206\/42935\/P\/TELOMERIC-ALLELIC-IMBALANCE-INDICATES-DEFECTIVE.","journal-title":"Cancer Discov"},{"key":"5850_CR6","doi-asserted-by":"publisher","unstructured":"Carroll D, McEwen R, Kozarewa I et al (2019) Correlation of circulating tumor DNA (ctDNA), tissue-based genomic profiling and clinical efficacy in the biomarker directed Ph1b trial in metastatic bladder cancer (BISCAY). 4553\u20134553. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_SUPPL.4553. https:\/\/doi.org\/101200\/JCO20193715_suppl4553 37","DOI":"10.1200\/JCO.2019.37.15_SUPPL.4553"},{"key":"5850_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","volume":"81","author":"R Cathomas","year":"2022","unstructured":"Cathomas R, Lorch A, Bruins HM et al (2022) The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. Eur Urol 81:95\u2013103","journal-title":"Eur Urol"},{"key":"5850_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00011","volume":"1","author":"D Chakravarty","year":"2017","unstructured":"Chakravarty D, Gao J, Phillips S et al (2017) OncoKB: a Precision Oncology Knowledge Base. JCO Precis Oncol 1:1\u201316. https:\/\/doi.org\/10.1200\/PO.17.00011","journal-title":"JCO Precis Oncol"},{"key":"5850_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/J.CCR.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi W, Porten S, Kim S et al (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25:152\u2013165. https:\/\/doi.org\/10.1016\/J.CCR.2014.01.009","journal-title":"Cancer Cell"},{"key":"5850_CR44","unstructured":"R Core Team (2020) R Core Team (2020)"},{"key":"5850_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1200\/JCO.22.00405","volume":"41","author":"SJ Crabb","year":"2023","unstructured":"Crabb SJ, Hussain S, Soulis E et al (2023) A Randomized, Double-Blind, Biomarker-Selected, phase II clinical trial of maintenance poly ADP-Ribose polymerase inhibition with Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma. J Clin Oncol 41:54\u201364. https:\/\/doi.org\/10.1200\/JCO.22.00405","journal-title":"J Clin Oncol"},{"key":"5850_CR12","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1073\/PNAS.1318376111","volume":"111","author":"JS Damrauer","year":"2014","unstructured":"Damrauer JS, Hoadley KA, Chism DD et al (2014) Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 111:3110\u20133115. https:\/\/doi.org\/10.1073\/PNAS.1318376111","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5850_CR11","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1038\/s41467-022-33980-9","volume":"13","author":"JS Damrauer","year":"2022","unstructured":"Damrauer JS, Beckabir W, Klomp J et al (2022) Collaborative study from the bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer. Nat Commun 13:6658. https:\/\/doi.org\/10.1038\/s41467-022-33980-9","journal-title":"Nat Commun"},{"key":"5850_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/S00428-017-2119-X\/FIGURES\/7","volume":"471","author":"ML Eich","year":"2017","unstructured":"Eich ML, Dyrskj\u00f8t L, Netto GJ (2017) Toward personalized management in bladder cancer: the promise of novel molecular taxonomy. Virchows Arch 471:271\u2013280. https:\/\/doi.org\/10.1007\/S00428-017-2119-X\/FIGURES\/7","journal-title":"Virchows Arch"},{"key":"5850_CR14","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/JAMA.2011.1142","volume":"306","author":"ND Freedman","year":"2011","unstructured":"Freedman ND, Silverman DT, Hollenbeck AR et al (2011) Association between smoking and risk of bladder cancer among men and women. JAMA 306:737\u2013745. https:\/\/doi.org\/10.1001\/JAMA.2011.1142","journal-title":"JAMA"},{"key":"5850_CR15","doi-asserted-by":"publisher","unstructured":"Fulton B, Jones R, Powles T et al (2020) ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer. Trials 21. https:\/\/doi.org\/10.1186\/S13063-020-04283-5","DOI":"10.1186\/S13063-020-04283-5"},{"key":"5850_CR16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.clgc.2023.07.009","volume":"21","author":"T Gamba","year":"2023","unstructured":"Gamba T, Paparo J, Panepinto O et al (2023) Poly (ADP-Ribose) polymerase inhibitors in patients with Urothelial Cancer. Clin Genitourin Cancer 21:509\u2013516. https:\/\/doi.org\/10.1016\/j.clgc.2023.07.009","journal-title":"Clin Genitourin Cancer"},{"key":"5850_CR17","doi-asserted-by":"publisher","unstructured":"Goutas D, Palamaris K, Stofas A et al (2023) Immunohistochemical Study of Bladder Cancer Molecular Subtypes and Their Association with PD-L1 expression. Cancers (Basel) 15. https:\/\/doi.org\/10.3390\/cancers15010188","DOI":"10.3390\/cancers15010188"},{"key":"5850_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08085-z","author":"P Grivas","year":"2021","unstructured":"Grivas P, Loriot Y, Morales-Barrera R et al (2021) Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS). BMC Cancer. https:\/\/doi.org\/10.1186\/s12885-021-08085-z. 21:","journal-title":"BMC Cancer"},{"key":"5850_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/JCO.22.01643\/SUPPL_FILE\/PROTOCOL_JCO.22.01643.PDF","volume":"41","author":"CJ Hoimes","year":"2023","unstructured":"Hoimes CJ, Flaig TW, Milowsky MI et al (2023) Enfortumab Vedotin Plus Pembrolizumab in previously untreated Advanced Urothelial Cancer. J Clin Oncol 41:22\u201331. https:\/\/doi.org\/10.1200\/JCO.22.01643\/SUPPL_FILE\/PROTOCOL_JCO.22.01643.PDF","journal-title":"J Clin Oncol"},{"key":"5850_CR20","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.celrep.2018.03.093","volume":"23","author":"HM Hu","year":"2018","unstructured":"Hu HM, Zhao X, Kaushik S et al (2018) A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP inhibitor resistance. Cell Rep 23:918\u2013929. https:\/\/doi.org\/10.1016\/j.celrep.2018.03.093","journal-title":"Cell Rep"},{"key":"5850_CR21","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/J.EURURO.2016.02.028","volume":"70","author":"PA Humphrey","year":"2016","unstructured":"Humphrey PA, Moch H, Cubilla AL et al (2016) The 2016 WHO classification of Tumours of the urinary system and male genital organs-Part B: prostate and bladder tumours. Eur Urol 70:106\u2013119. https:\/\/doi.org\/10.1016\/J.EURURO.2016.02.028","journal-title":"Eur Urol"},{"key":"5850_CR22","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, de Reyni\u00e8s A, Allory Y et al (2020) A Consensus Molecular classification of muscle-invasive bladder Cancer. Eur Urol 77:420\u2013433. https:\/\/doi.org\/10.1016\/j.eururo.2019.09.006","journal-title":"Eur Urol"},{"key":"5850_CR23","doi-asserted-by":"publisher","unstructured":"Lavallee E, Sfakianos JP, Mulholland DJ (2021) Tumor heterogeneity and consequences for bladder cancer treatment. Cancers (Basel) 13. https:\/\/doi.org\/10.3390\/CANCERS13215297","DOI":"10.3390\/CANCERS13215297"},{"key":"5850_CR24","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1158\/1078-0432.CCR-18-1001","volume":"25","author":"Q Li","year":"2019","unstructured":"Li Q, Damish AW, Frazier Z et al (2019) ERCC2 helicase domain mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in muscle-invasive bladder Cancer. Clin Cancer Res 25:977\u2013988. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1001","journal-title":"Clin Cancer Res"},{"key":"5850_CR25","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2016.1056","volume":"2","author":"D Liu","year":"2016","unstructured":"Liu D, Plimack ER, Hoffman-Censits J et al (2016) Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma. JAMA Oncol 2:1094\u20131096","journal-title":"JAMA Oncol"},{"key":"5850_CR26","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","volume":"10","author":"PJ Loehrer","year":"1992","unstructured":"Loehrer PJ, Einhorn LH, Elson PJ et al (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10:1066\u20131073. https:\/\/doi.org\/10.1200\/JCO.1992.10.7.1066","journal-title":"J Clin Oncol"},{"key":"5850_CR27","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/nejmoa1817323","volume":"381","author":"Y Loriot","year":"2019","unstructured":"Loriot Y, Necchi A, Park SH et al (2019) Erdafitinib in locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 381:338\u2013348. https:\/\/doi.org\/10.1056\/nejmoa1817323","journal-title":"N Engl J Med"},{"key":"5850_CR28","doi-asserted-by":"publisher","unstructured":"Marzouka NAD, Eriksson P, Rovira C et al (2018) A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort. Sci Rep 8. https:\/\/doi.org\/10.1038\/S41598-018-22126-X","DOI":"10.1038\/S41598-018-22126-X"},{"key":"5850_CR29","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/GR.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin DC, Assenov Y et al (2018) Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res 28:1747\u20131756. https:\/\/doi.org\/10.1101\/GR.239244.118","journal-title":"Genome Res"},{"key":"5850_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13059-016-0974-4\/TABLES\/8","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren W, Gil L, Hunt SE et al (2016) The Ensembl variant effect predictor. Genome Biol 17:1\u201314. https:\/\/doi.org\/10.1186\/S13059-016-0974-4\/TABLES\/8","journal-title":"Genome Biol"},{"key":"5850_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/S41585-020-0304-1","volume":"17","author":"JJ Meeks","year":"2020","unstructured":"Meeks JJ, Al-Ahmadie H, Faltas BM et al (2020) Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nat Rev Urol 17:259\u2013270. https:\/\/doi.org\/10.1038\/S41585-020-0304-1","journal-title":"Nat Rev Urol"},{"key":"5850_CR32","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/J.CLLC.2021.04.003","volume":"22","author":"CM Merkhofer","year":"2021","unstructured":"Merkhofer CM, Eaton KD, Martins RG et al (2021) Impact of clinical trial participation on survival of patients with metastatic non-small cell Lung Cancer. Clin Lung Cancer 22:523. https:\/\/doi.org\/10.1016\/J.CLLC.2021.04.003","journal-title":"Clin Lung Cancer"},{"key":"5850_CR33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/1756287216638981","volume":"8","author":"AP Mitra","year":"2016","unstructured":"Mitra AP (2016) Molecular substratification of bladder cancer: moving towards individualized patient management. Ther Adv Urol 8:215\u2013233. https:\/\/doi.org\/10.1177\/1756287216638981","journal-title":"Ther Adv Urol"},{"key":"5850_CR34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/JU.0000000000000351","volume":"203","author":"DS Morera","year":"2020","unstructured":"Morera DS, Hasanali SL, Belew D et al (2020) Clinical parameters Outperform Molecular subtypes for Predicting Outcome in bladder Cancer: results from multiple cohorts, including TCGA. J Urol 203:62\u201372. https:\/\/doi.org\/10.1097\/JU.0000000000000351","journal-title":"J Urol"},{"key":"5850_CR35","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1200\/JCO.22.02887","volume":"41","author":"PH O\u2019Donnell","year":"2023","unstructured":"O\u2019Donnell PH, Milowsky MI, Petrylak DP et al (2023) Enfortumab Vedotin with or without Pembrolizumab in Cisplatin-Ineligible patients with previously untreated locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol 41:4107\u20134117. https:\/\/doi.org\/10.1200\/JCO.22.02887","journal-title":"J Clin Oncol"},{"key":"5850_CR36","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.eururo.2015.02.021","volume":"68","author":"O Patschan","year":"2015","unstructured":"Patschan O, Sj\u00f6dahl G, Chebil G et al (2015) A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma. Eur Urol 68:824\u2013832. https:\/\/doi.org\/10.1016\/j.eururo.2015.02.021","journal-title":"Eur Urol"},{"key":"5850_CR37","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.eururo.2017.12.011","volume":"73","author":"R Peeker","year":"2018","unstructured":"Peeker R (2018) Re: molecular classification of Urothelial Carcinoma: global mRNA classification Versus Tumour-cell phenotype classification. Eur Urol 73:809\u2013810. https:\/\/doi.org\/10.1016\/j.eururo.2017.12.011","journal-title":"Eur Urol"},{"key":"5850_CR38","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1002\/IJC.28892","volume":"135","author":"Y Peng","year":"2014","unstructured":"Peng Y, Li Z, Zhang S et al (2014) Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients. Int J Cancer 135:2687\u20132696. https:\/\/doi.org\/10.1002\/IJC.28892","journal-title":"Int J Cancer"},{"key":"5850_CR42","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/nejmoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E et al (2020) Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 383:1218\u20131230. https:\/\/doi.org\/10.1056\/nejmoa2002788","journal-title":"N Engl J Med"},{"key":"5850_CR39","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s41591-021-01317-6","volume":"27","author":"T Powles","year":"2021","unstructured":"Powles T, Carroll D, Chowdhury S et al (2021a) An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. Nat Med 27:793\u2013801. https:\/\/doi.org\/10.1038\/s41591-021-01317-6","journal-title":"Nat Med"},{"key":"5850_CR40","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/S41591-021-01317-6","volume":"27","author":"T Powles","year":"2021","unstructured":"Powles T, Carroll D, Chowdhury S et al (2021b) An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. Nat Med 27:793\u2013801. https:\/\/doi.org\/10.1038\/S41591-021-01317-6","journal-title":"Nat Med"},{"key":"5850_CR41","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.22.01792","volume":"41","author":"T Powles","year":"2023","unstructured":"Powles T, Park SH, Caserta C et al (2023) Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: results from the JAVELIN bladder 100 Trial after \u2265\u20092 years of Follow-Up. J Clin Oncol 41:3486\u20133492. https:\/\/doi.org\/10.1200\/JCO.22.01792","journal-title":"J Clin Oncol"},{"key":"5850_CR43","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMOA2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S et al (2024) Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med 390:875\u2013888. https:\/\/doi.org\/10.1056\/NEJMOA2312117","journal-title":"N Engl J Med"},{"key":"5850_CR45","doi-asserted-by":"publisher","unstructured":"Rebouissou S, Bernard-Pierrot I, De Reyni\u00e8s A et al (2014) EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med 6. https:\/\/doi.org\/10.1126\/SCITRANSLMED.3008970","DOI":"10.1126\/SCITRANSLMED.3008970"},{"key":"5850_CR46","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/J.CELL.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H et al (2017) Comprehensive molecular characterization of muscle-invasive bladder Cancer. Cell 171:540\u2013556e25. https:\/\/doi.org\/10.1016\/J.CELL.2017.09.007","journal-title":"Cell"},{"key":"5850_CR47","doi-asserted-by":"publisher","unstructured":"Safiri S, Kolahi AA, Naghavi M et al (2021) Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease study 2019. BMJ Glob Health 6. https:\/\/doi.org\/10.1136\/BMJGH-2020-004128","DOI":"10.1136\/BMJGH-2020-004128"},{"key":"5850_CR48","doi-asserted-by":"publisher","unstructured":"Saginala K, Barsouk A, Aluru JS et al (2020) Epidemiology of {Bladder} {Cancer}. Med Sci (Basel) 8. https:\/\/doi.org\/10.3390\/medsci8010015","DOI":"10.3390\/medsci8010015"},{"key":"5850_CR49","doi-asserted-by":"publisher","first-page":"e17041","DOI":"10.1200\/jco.2020.38.15_suppl.e17041","volume":"38","author":"GB Schulz","year":"2020","unstructured":"Schulz GB, Todorova R, Rodler S et al (2020) Heterogeneity of PD-L1 expression between primary and metastatic bladder cancer tumors and therapeutic implications between the immune cell score and combined positivity score. J Clin Oncol 38:e17041\u2013e17041. https:\/\/doi.org\/10.1200\/jco.2020.38.15_suppl.e17041","journal-title":"J Clin Oncol"},{"key":"5850_CR50","doi-asserted-by":"crossref","unstructured":"Sj\u00f6dahl G (2018) Molecular subtype profiling of urothelial carcinoma using a subtype-specific immunohistochemistry panel. Methods in Molecular Biology. Humana Press Inc., pp 53\u201364","DOI":"10.1007\/978-1-4939-7234-0_5"},{"key":"5850_CR52","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/path.4886","volume":"242","author":"G Sj\u00f6dahl","year":"2017","unstructured":"Sj\u00f6dahl G, Eriksson P, Liedberg F, H\u00f6glund M (2017) Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. J Pathol 242:113\u2013125. https:\/\/doi.org\/10.1002\/path.4886","journal-title":"J Pathol"},{"key":"5850_CR53","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/path.5230","volume":"247","author":"G Sj\u00f6dahl","year":"2019","unstructured":"Sj\u00f6dahl G, Jackson CL, Bartlett JMS et al (2019) Molecular profiling in muscle-invasive bladder cancer: more than the sum of its parts. J Pathol 247:563\u2013573","journal-title":"J Pathol"},{"key":"5850_CR51","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.3390\/cancers14071692","volume":"14","author":"G Sj\u00f6dahl","year":"2022","unstructured":"Sj\u00f6dahl G, Abrahamsson J, Bernardo C et al (2022) Molecular subtypes as a basis for stratified use of Neoadjuvant Chemotherapy for muscle-invasive bladder Cancer\u2014A narrative review. Cancers (Basel) 14:1692","journal-title":"Cancers (Basel)"},{"key":"5850_CR54","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1158\/2159-8290.CD-23-0467\/3372948\/CD-23-0467.PDF","volume":"14","author":"SP Suehnholz","year":"2023","unstructured":"Suehnholz SP, Nissan MH, Zhang H et al (2023) Quantifying the Expanding Landscape of clinical actionability for patients with Cancer. Cancer Discov 14:49\u201365. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0467\/3372948\/CD-23-0467.PDF","journal-title":"Cancer Discov"},{"key":"5850_CR55","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/CAAC.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/CAAC.21660","journal-title":"CA Cancer J Clin"},{"key":"5850_CR56","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1158\/1078-0432.CCR-18-1780","volume":"25","author":"IV Tuxen","year":"2019","unstructured":"Tuxen IV, Rohrberg KS, Oestrup O et al (2019) Copenhagen prospective personalized oncology (COPPO)\u2014Clinical utility of using molecular profiling to select patients to phase I trials. Clin Cancer Res 25:1239\u20131247. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1780","journal-title":"Clin Cancer Res"},{"key":"5850_CR57","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","volume":"4","author":"EM Van Allen","year":"2014","unstructured":"Van Allen EM, Mouw KW, Kim P et al (2014) Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 4:1140\u20131153. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0623","journal-title":"Cancer Discov"},{"key":"5850_CR58","doi-asserted-by":"publisher","unstructured":"Vandekerkhove G, Lavoie J-M, Annala M et al (2019) Genomic concordance between profiling of circulating tumor DNA (ctDNA) and matched tissue in metastatic urothelial carcinoma. 457\u2013457. https:\/\/doi.org\/10.1200\/JCO.2019.37.7_SUPPL.457. https:\/\/doi.org\/101200\/JCO2019377_suppl457 37","DOI":"10.1200\/JCO.2019.37.7_SUPPL.457"},{"key":"5850_CR59","doi-asserted-by":"publisher","unstructured":"Venkatesan S, Swanton C, Taylor BS, Costello JF (2017) Treatment-Induced mutagenesis and selective pressures sculpt Cancer Evolution. Cold Spring Harb Perspect Med 7. https:\/\/doi.org\/10.1101\/CSHPERSPECT.A026617","DOI":"10.1101\/CSHPERSPECT.A026617"},{"key":"5850_CR60","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2022.09.025","volume":"83","author":"F Vignani","year":"2023","unstructured":"Vignani F, Tambaro R, De Giorgi U et al (2023) Addition of Niraparib to best supportive care as maintenance treatment in patients with Advanced Urothelial Carcinoma whose disease did not Progress after First-line platinum-based Chemotherapy: the Meet-URO12 Randomized Phase 2 Trial. Eur Urol 83:82\u201389. https:\/\/doi.org\/10.1016\/j.eururo.2022.09.025","journal-title":"Eur Urol"},{"key":"5850_CR61","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H Von der Maase","year":"2000","unstructured":"Von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068\u20133077. https:\/\/doi.org\/10.1200\/JCO.2000.18.17.3068","journal-title":"J Clin Oncol"},{"issue":"1 6","key":"5850_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep26526","volume":"6","author":"C Wang","year":"2016","unstructured":"Wang C, Nie H, Li Y et al (2016) The study of the relation of DNA repair pathway genes SNPs and the sensitivity to radiotherapy and chemotherapy of NSCLC. Sci Rep 2016 6(1 6):1\u201312. https:\/\/doi.org\/10.1038\/srep26526","journal-title":"Sci Rep 2016"},{"key":"5850_CR63","doi-asserted-by":"publisher","unstructured":"Waskiewicz E, Vasiliou M, Corcoles-Saez I, Cha RS (2021) Cancer genome datamining and functional genetic analysis implicate mechanisms of ATM\/ATR dysfunction underpinning carcinogenesis. Commun Biol 4(1):363. https:\/\/doi.org\/10.1038\/s42003-021-01884-x","DOI":"10.1038\/s42003-021-01884-x"},{"key":"5850_CR64","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1097\/JU.0000000000000350","volume":"202","author":"DO Westergren","year":"2019","unstructured":"Westergren DO, G\u00e5rdmark T, Lindhagen L et al (2019) A Nationwide, Population based analysis of patients with Organ confined, muscle invasive bladder Cancer not receiving curative intent therapy in Sweden from 1997 to 2014. J Urol 202:905\u2013912. https:\/\/doi.org\/10.1097\/JU.0000000000000350","journal-title":"J Urol"},{"key":"5850_CR65","doi-asserted-by":"crossref","unstructured":"Witjes JA, Bruins HM, Cathomas R et al (2021) European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol 79:82\u2013104 (2013) World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 310:2191\u20132194","DOI":"10.1016\/j.eururo.2020.08.014"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05850-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05850-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05850-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T17:07:22Z","timestamp":1723050442000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05850-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":65,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["5850"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05850-y","relation":{},"ISSN":["1432-1335"],"issn-type":[{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2024,7,8]]},"assertion":[{"value":"13 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D.R.S. received educational and research funding from Pfizer and Merck Serono for other projects unrelated to this study, served on advisory boards for Merck Sharp and Dome (MSD), Bristol Meyers Squibb and Johnson and Johnson, unrelated to this study; K.S.R: No COI to report; K.W.M: Advisory\/consulting work for EMD Serono, Pfizer, UroGen, and Riva Therapeutics; has received research support from Pfizer and Novo Ventures; has equity in Riva Therapeutics; has received writing\/editor fees from UpToDate; has received speaking fees from OncLive; and is a co-inventor listed on an institutional patent application for analysis of mutational signatures of DNA repair deficiency; K.\u00d8: No COI to report, F.O.B: received personal fees from AstraZeneca, and served as scientific advisor through ownership of FOBinf for Immunitrack, Hervolution and Aida Oncology unrelated to this work, Z.S: Research funding from Lantern Pharma Inc; M.R: received personal fees from AstraZeneca and MSD and served on advisory board of MSD outside the submitted work.; H.P: Research funding from Pfizer and Merck unrelated to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"339"}}